Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study

• Asıl Yazarlar: Juul M.P.A. van den Reek (Yazar), Lieke J. van Vugt (Yazar), Martijn B.A. van Doorn (Yazar), Gayle E. van der Kraaij (Yazar), Wim J.A. de Kort (Yazar), Georges P.H. Lucker (Yazar), Barbara Horvath (Yazar), M. David Njoo (Yazar), H. Jorn Bovenschen (Yazar), Paul M. Ossenkoppele (Yazar), Marjolein S. De Bruin-Weller (Yazar), Marjan de Groot (Yazar), Roland Mommers (Yazar), Ruud L.M.A. Prevoo (Yazar), Peter C.M. van de Kerkhof (Yazar), Phyllis I. Spuls (Yazar), Wietske Kievit (Yazar), Elke M.G.J. de Jong (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Medical Journals Sweden, 2018-04-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Interleukin 17-antagonist secukinumab demonstrated high efficacy for treatment of psoriasis in randomized controlled trials. However, performance in daily practice may differ from trials. Drug survival is a comprehensive outcome covering effectiveness and safety, suitable for analyses of daily pract...